ClinicalTrials.gg
CompletedNCT01171976RETAINUpdated Sep 15, 2014Results posted

Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus

A Phase 3 interventional study of Ranibizumab in Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 68 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
10th of 91
373 · median 50
Started
2010
with 4 others
Phase 3
25 of 91
none open now
Registered
24th of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 10th largest by enrollment, is one of 5 that started in 2010, is one of 25 in phase 3, and was the 24th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

The purpose of this study is to demonstrate that two investigational treatment regimens have the potential to result in a superior visual acuity improvement as compared to a ranibizumab pro re nata (PRN=as needed) treatment regimen.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

Keywords

  • DME
  • Diabetic macula edema
  • RETAIN
  • ranibizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient

  • Patients with Type 1 or Type 2 diabetes mellitus (according to American Diabetes Association or World Health Organization [WHO] guidelines) with glycosylated () ≤ 12.0% at screening (Visit 1). Patients should be on diet, exercise, and/or pharmacological treatment for diabetes. Treatment for diabetes must have been stable for at least 3 month.

Ocular

  • Patients with visual impairment due to DME in at least one eye who are eligible for laser treatment in the opinion of the investigator. If both eyes are eligible, the one with the worse visual acuity, as assessed at Visit 1, will be selected by the investigator as the study eye.
  • BCVA ≥ 39 and ≤78 letters in the study eye and, inclusively, using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters (approximate Snellen equivalent of 20/32 to 20/160) at screening.
  • Concomitant conditions in the study eye are only permitted if, in the opinion of the investigator, they do not prevent improvement of visual acuity on study treatment.

Exclusion criteria

Exclusion Criteria:

Patient Compliance/ Administrative

  • Pregnant or nursing (lactating) women.

Ocular medical history

  • Active intraocular inflammation (grade trace or above) in either eye at enrollment.
  • Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye at the time of enrollment.
  • History of uveitis in either eye at any time.
  • Structural damage within 0.5 disc diameter of the center of the macular in the study eye likely to preclude improvement in visual acuity following the resolution of macular edema.
  • Uncontrolled glaucoma in either eye at screening.

Prior Ocular treatments

  • Panretinal laser photocoagulation in the study eye within 6 months prior to randomization.
  • Focal/grid laser photocoagulation in the study eye within 3 months prior to randomization.
  • Treatment with anti-angiogenic drugs in either eye.

Systemic conditions or treatments

  • History of stroke within 6 months prior to enrollment.
  • Renal failure requiring dialysis.
  • Untreated diabetes mellitus.
  • Blood pressure systolic > 160 mmHg or diastolic > 100 mmHg.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    TE Ranibizumab 0.5 mg and Laser

    On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.

    Drug: Ranibizumab

  • Experimental
    TE Ranibizumab 0.5 mg alone

    Patients received ranibizumab intravitreal injection therapy only.

    Drug: Ranibizumab

  • Active comparator
    PRN Ranibizumab 0.5 mg

    Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.

    Drug: Ranibizumab

Interventions

  • Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.

06

What researchers measure

Primary outcomes

  1. Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12

    Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 24

    Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

    Time frame: Baseline to Month 24

  2. Visual Acuity of the Study Eye: Change From Baseline at Month 12

    Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

    Time frame: Baseline and Month 12

  3. Visual Acuity of the Study Eye: Change From Baseline at Month 24

    Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

    Time frame: Baseline and Month 24

  4. Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 12

    Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

    Time frame: Baseline, Month 12

  5. Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 24

    Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

    Time frame: Baseline, 24 month

  6. Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12

    High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.

    Time frame: Baseline, Month 12

  7. Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24

    High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.

    Time frame: Baseline and 24 month

  8. Visual Functioning Questionnaire (VFQ-25) Change From Baseline in Total Score at Month 12 and Month 24

    The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and symptoms on general health. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. Each response was recoded per the scoring rules outlined in the National Eye Institute (NEI) VFQ-25 Scoring Algorithm. Under this scoring algorithm , the recoded values range between 0 and 100 and a high score means a better functioning

    Time frame: Baseline, Month 12 and Month 24

  9. EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24

    The Euro Quality of Life Questionnaire (EQ-5D) is an indirect utility questionnaire. It is a standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1= "no problems", 2="some problems" and 3="extreme problems" . A composite health index was then defined by combining the levels for each dimension. Overall, 243 health states are possible. For each health state, the EuroQol group has assigned a utility value typically between 0 and 1 with lower scores representing a higher level of dysfunction

    Time frame: Baseline, Month 12 and Month 24

07

Results

Posted Sep 15, 2014

Participant flow

A total of 373 patients with macular edema and visual impairment secondary to DME were enrolled. A total of 372 patients were randomized. One patient was excluded from all analyses due to administrative problems

Participant flow — Overall Study
MilestoneTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Started121128123
Safety set126126118
Completed107117108
Not completed141115
Withdrew: Protocol violation001
Withdrew: Death241
Withdrew: Lost to follow-up402
Withdrew: Withdrawal by subject156
Withdrew: Abnormal test result100
Withdrew: Adverse event625

Outcome measures

PrimaryVisual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12

Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

Time frame:
Baseline to Month 12
Reported as:
Mean · Letters
Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12
LettersTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Baseline62.3 ± 11.5064.1 ± 10.5265.1 ± 10.08
Average Month 1 to Month 1268.25 ± 11.05770.28 ± 10.28471.32 ± 9.984
Average Change from Baseline5.91 ± 5.5326.14 ± 5.7176.20 ± 6.005
SecondaryVisual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 24

Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

Time frame:
Baseline to Month 24
Reported as:
Mean · Letters
Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 24
LettersTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Baseline62.3 ± 11.5064.1 ± 10.5265.1 ± 10.08
Average Month 1 to Month 2469.12 ± 11.26170.72 ± 10.92472.09 ± 10.141
Average Change from Baseline6.78 ± 5.9866.58 ± 7.0706.97 ± 6.430
SecondaryVisual Acuity of the Study Eye: Change From Baseline at Month 12

Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

Time frame:
Baseline and Month 12
Reported as:
Mean · Letters
Visual Acuity of the Study Eye: Change From Baseline at Month 12
LettersTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Baseline62.3 ± 11.5065.1 ± 10.5265.1 ± 10.08
Month 1269.13 ± 11.94570.93 ± 11.74272.56 ± 11.592
Change from Baseline6.79 ± 6.9996.80 ± 8.7267.44 ± 8.457
SecondaryVisual Acuity of the Study Eye: Change From Baseline at Month 24

Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

Time frame:
Baseline and Month 24
Reported as:
Mean · Letters
Visual Acuity of the Study Eye: Change From Baseline at Month 24
LettersTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Baseline62.3 ± 11.5064.1 ± 10.5265.1 ± 10.08
Month 2470.64 ± 12.31570.62 ± 13.48173.18 ± 11.872
Change from Baseline8.30 ± 8.1296.49 ± 10.8548.06 ± 8.462
SecondaryVisual Acuity of the Study Eye: Categorized Change From Baseline at Month 12

Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

Time frame:
Baseline, Month 12
Reported as:
Number · Percentage of patients
Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 12
Percentage of patientsTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Gain of >= 1 letter82.984.883.8
Gain of >= 5 letters59.060.870.1
Gain of >= 10 letters32.542.439.3
Gain of >= 15 letters19.730.426.5
Loss of >= 5 letters3.44.03.4
Loss of >= 10 letters0.02.40.9
Loss of >= 15 letters0.01.60.9
SecondaryVisual Acuity of the Study Eye: Categorized Change From Baseline at Month 24

Visual acuity was assessed at every study visit for the study eye using best correction determined from protocol refraction. The BCVA measurements were taken in a sitting position using ETDRS-like VA testing charts at a starting distance of 4 meters.

Time frame:
Baseline, 24 month
Reported as:
Number · Percentage of pateints
Visual Acuity of the Study Eye: Categorized Change From Baseline at Month 24
Percentage of pateintsTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Gain of >= 1 letter87.284.090.6
Gain of >= 5 letters69.262.476.1
Gain of >= 10 letters43.640.845.3
Gain of >= 15 letters25.628.030.8
Loss of >= 5 letters4.38.05.1
Loss of >= 10 letters2.67.23.4
Loss of >= 15 letters0.94.02.6
SecondaryCentral Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12

High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.

Time frame:
Baseline, Month 12
Reported as:
Mean · Percent Change
Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12
Percent ChangeTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 12-27.09 ± 22.992-24.35 ± 22.027-23.16 ± 22.362
SecondaryCentral Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24

High Resolution OCT was performed at every study visit by Spectral Domain OCT (if not available Time Domain OCT was acceptable) and the images were transferred to a digital video disc. These assessments were performed by trained and adequately qualified experts at the sites and prior to any study drug administration. CSFT is the average retinal thickness of the circular area with 1 mm diameter around the foveal center.

Time frame:
Baseline and 24 month
Reported as:
Mean · Percent Change
Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24
Percent ChangeTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Central Subfield Thickness of the Study Eye: Percent Change From Baseline at Month 24-32.03 ± 25.628-24.98 ± 26.414-24.97 ± 26.678
SecondaryVisual Functioning Questionnaire (VFQ-25) Change From Baseline in Total Score at Month 12 and Month 24

The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and symptoms on general health. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. Each response was recoded per the scoring rules outlined in the National Eye Institute (NEI) VFQ-25 Scoring Algorithm. Under this scoring algorithm , the recoded values range between 0 and 100 and a high score means a better functioning

Time frame:
Baseline, Month 12 and Month 24
Reported as:
Mean · Score on a scale
Visual Functioning Questionnaire (VFQ-25) Change From Baseline in Total Score at Month 12 and Month 24
Score on a scaleTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Baseline (n=116,122,114)75.32 ± 17.31775.47 ± 17.10577.07 ± 18.581
Change from baseline at Month 12 (n=116,122,114)4.60 ± 10.9053.95 ± 10.9415.41 ± 12.063
Change from baseline at month 24 (n=116,122,114)4.06 ± 11.8592.31 ± 13.2705.96 ± 12.389
SecondaryEuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24

The Euro Quality of Life Questionnaire (EQ-5D) is an indirect utility questionnaire. It is a standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1= "no problems", 2="some problems" and 3="extreme problems" . A composite health index was then defined by combining the levels for each dimension. Overall, 243 health states are possible. For each health state, the EuroQol group has assigned a utility value typically between 0 and 1 with lower scores representing a higher level of dysfunction

Time frame:
Baseline, Month 12 and Month 24
Reported as:
Mean · Score on a scale
EuroQoL (EQ-5D) Thermometer Score: Change From Baseline at Month 12 and Month 24
Score on a scaleTE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Baseline71.4 ± 17.3670.7 ± 16.1072.2 ± 13.24
Change from Baseline at Month 12 (n=115,123,113)0.47 ± 16.4870.91 ± 13.4222.52 ± 14.431
Change from Baseline at Month 24 (n=115,123,113)1.35 ± 17.4640.11 ± 14.7551.98 ± 14.812

Adverse events

Non-serious events are listed at a 1.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TE Ranibizumab 0.5 mg and Laser—34/126 (27%)98/126 (77.8%)
TE Ranibizumab 0.5 mg Alone—29/126 (23%)101/126 (80.2%)
PRN Ranibizumab 0.5 mg—26/118 (22%)78/118 (66.1%)
Most frequent serious events
Showing 10 of 120
Most frequent serious events
EventTE Ranibizumab 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
Myocardial infarctionCardiac disorders4/1261/1261/118
Cerebrovascular accidentNervous system disorders1/1262/1263/118
PneumoniaInfections and infestations3/1261/1260/118
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1260/1262/118
Acute myocardial infarctionCardiac disorders0/1262/1260/118
Atrial fibrillationCardiac disorders0/1262/1260/118
Myocardial ischaemiaCardiac disorders0/1262/1261/118
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1262/1260/118
Skin ulcerSkin and subcutaneous tissue disorders0/1262/1260/118
AnaemiaBlood and lymphatic system disorders0/1260/1261/118
Most frequent other events
Showing 10 of 166
Most frequent other events
EventTE Ranibizumab 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mg
HypertensionVascular disorders19/12617/1268/118
Conjunctival haemorrhage (Study eye)Eye disorders5/12611/1266/118
BronchitisInfections and infestations11/1261/1265/118
NasopharyngitisInfections and infestations11/12610/1268/118
InfluenzaInfections and infestations9/12610/1268/118
Urinary tract infectionInfections and infestations9/12610/1265/118
Back painMusculoskeletal and connective tissue disorders8/12610/1263/118
Eye pain (Study eye)Eye disorders8/1267/1263/118
Vitreous haemorrhage (Study eye)Eye disorders8/1262/1260/118
Cataract (Study eye)Eye disorders5/1267/1267/118

Baseline characteristics

The Randomized Set comprised all randomized patients, ie those given a randomization number.

Age, Continuous
Age, Continuous(Years)TE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mgTotal
Mean63.7 ± 9.0763.0 ± 9.8364.5 ± 9.6663.7 ± 9.53
Sex: Female, Male
Sex: Female, Male(Participants)TE Ranibizumad 0.5 mg and LaserTE Ranibizumab 0.5 mg AlonePRN Ranibizumab 0.5 mgTotal
Female435146140
Male787777232
08

Study locations

68 sites
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Kortrijk, 8500, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Hradec Kralove, 505 05, Czech Republic
  • Novartis Investigative Site
    Olomouc, 775 20, Czech Republic
  • Novartis Investigative Site
    Plzen, 301 00, Czech Republic
  • Novartis Investigative Site
    Prague 2, 128 08, Czech Republic
  • Novartis Investigative Site
    Praha 6, 169 02, Czech Republic
  • Novartis Investigative Site
    Bordeaux, 33 000, France
  • Novartis Investigative Site
    Dijon, 21034, France
  • Novartis Investigative Site
    Lille, 59 037, France
  • Novartis Investigative Site
    Limoges Cedex, 87042, France
  • Novartis Investigative Site
    Lyon, 69003, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Nice, 6 000, France
  • Novartis Investigative Site
    Paris cedex 10, 75475, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Heraklion Crete, Crete GR-71110, Greece
  • Novartis Investigative Site
    Athens, 152 31, Greece
  • Novartis Investigative Site
    Thessaloniki, 546 36, Greece
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Budapest, 1133, Hungary
  • Novartis Investigative Site
    Debrecen, 4012, Hungary
  • Novartis Investigative Site
    Gyor, 9024, Hungary
  • Novartis Investigative Site
    Dublin 7, Ireland
  • Novartis Investigative Site
    Dublin, Ireland
  • Novartis Investigative Site
    Kilkenny, Ireland
  • Novartis Investigative Site
    Limerick, Ireland
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Milano, MI 20122, Italy
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Milano, MI 20157, Italy
  • Novartis Investigative Site
    Roma, RM 00133, Italy
  • Novartis Investigative Site
    Roma, RM 00198, Italy
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Leiden 2333 ZA, 2333, Netherlands
  • Novartis Investigative Site
    Nijmegen, 6525 EX, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3011 BH, Netherlands
  • Novartis Investigative Site
    Bielsko-Biala, 43-300, Poland
  • Novartis Investigative Site
    Lublin, 20-954, Poland
  • Novartis Investigative Site
    Warszawa, 00-416, Poland
  • Novartis Investigative Site
    Wroclaw, 50-367, Poland
  • Novartis Investigative Site
    Coimbra, 3000-354, Portugal
  • Novartis Investigative Site
    Lisboa, 1150-199, Portugal
  • Novartis Investigative Site
    Porto, 4099-001, Portugal
  • Novartis Investigative Site
    Málaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Valladolid, Castilla y Leon 47011, Spain
  • Novartis Investigative Site
    L'Hospitalet de Llobregat, Cataluña 08907, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03016, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46015, Spain
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15705, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, 35016, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Bern, 3012, Switzerland
  • Novartis Investigative Site
    Binningen, 4102, Switzerland
  • Novartis Investigative Site
    Zürich, 8063, Switzerland
  • Novartis Investigative Site
    Frimley, Surrey GU16 7UJ, United Kingdom
  • Novartis Investigative Site
    Aberdeen, AB25 2ZN, United Kingdom
  • Novartis Investigative Site
    Bristol, BS1 2LX, United Kingdom
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • Novartis Investigative Site
    Manchester, M13 9WL, United Kingdom
  • Novartis Investigative Site
    Newcastle Upon Tyne, NE1 4LP, United Kingdom
  • Novartis Investigative Site
    Sheffield, S10 2JF, United Kingdom
  • Novartis Investigative Site
    Southampton, SO16 6YD, United Kingdom
  • Novartis Investigative Site
    Sunderland, SR2 9HP, United Kingdom
  • Novartis Investigative Site
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Publications

  • Prunte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnicka J, Bezlyak V, Parikh S, Stubbings WJ, Wenzel A, Figueira J; RETAIN Study Group. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016 Jun;100(6):787-95. doi: 10.1136/bjophthalmol-2015-307249. Epub 2015 Oct 9. PubMed 26453639 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2010
First posted
Jul 29, 2010
Start
Sep 2010
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results first posted
Sep 15, 2014
Last update
Sep 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01171976
Responsible party
Sponsor
First posted
Jul 29, 2010
Start date
Sep 2010
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
Sep 15, 2014
Last update
Sep 15, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion